Cabaletta Bio (CABA) Projected to Release Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Cabaletta Bio to post earnings of ($0.37) per share and revenue of $1.6670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. On average, analysts expect Cabaletta Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cabaletta Bio Stock Performance

CABA stock opened at $2.77 on Wednesday. The stock has a market cap of $450.83 million, a P/E ratio of -1.41 and a beta of 3.30. The firm has a 50 day simple moving average of $3.02 and a 200 day simple moving average of $3.05. Cabaletta Bio has a 52 week low of $1.26 and a 52 week high of $4.23.

Analysts Set New Price Targets

A number of research analysts have weighed in on CABA shares. Wall Street Zen lowered shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Wells Fargo & Company boosted their target price on shares of Cabaletta Bio from $2.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of Cabaletta Bio in a research note on Monday, May 4th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cabaletta Bio has an average rating of “Moderate Buy” and an average price target of $15.50.

Institutional Trading of Cabaletta Bio

A number of institutional investors and hedge funds have recently modified their holdings of CABA. Comerica Bank lifted its position in Cabaletta Bio by 2,292.1% in the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after purchasing an additional 39,860 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Cabaletta Bio in the 4th quarter valued at $58,000. Tower Research Capital LLC TRC increased its holdings in Cabaletta Bio by 695.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company’s stock valued at $78,000 after buying an additional 44,621 shares during the period. Invesco Ltd. increased its holdings in Cabaletta Bio by 357.1% in the 1st quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock valued at $85,000 after buying an additional 48,181 shares during the period. Finally, LPL Financial LLC acquired a new position in shares of Cabaletta Bio in the 4th quarter valued at $93,000.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.